李茂英, 刘海燕, 李曦. 声动力靶位药物传输联合HRZES方案治疗复治空洞型肺结核的疗效研究[J]. 蚌埠医学院学报, 2021, 46(10): 1432-1434. DOI: 10.13898/j.cnki.issn.1000-2200.2021.10.027
    引用本文: 李茂英, 刘海燕, 李曦. 声动力靶位药物传输联合HRZES方案治疗复治空洞型肺结核的疗效研究[J]. 蚌埠医学院学报, 2021, 46(10): 1432-1434. DOI: 10.13898/j.cnki.issn.1000-2200.2021.10.027
    LI Mao-ying, LIU Hai-yan, LI Xi. Therapeutic effect study of acoustic power target drug delivery combined with HRZES regimen in the retreatment of cavitary pulmonary tuberculosis[J]. Journal of Bengbu Medical College, 2021, 46(10): 1432-1434. DOI: 10.13898/j.cnki.issn.1000-2200.2021.10.027
    Citation: LI Mao-ying, LIU Hai-yan, LI Xi. Therapeutic effect study of acoustic power target drug delivery combined with HRZES regimen in the retreatment of cavitary pulmonary tuberculosis[J]. Journal of Bengbu Medical College, 2021, 46(10): 1432-1434. DOI: 10.13898/j.cnki.issn.1000-2200.2021.10.027

    声动力靶位药物传输联合HRZES方案治疗复治空洞型肺结核的疗效研究

    Therapeutic effect study of acoustic power target drug delivery combined with HRZES regimen in the retreatment of cavitary pulmonary tuberculosis

    • 摘要:
      目的研究声动力靶位药物传输联合HRZES方案治疗复治空洞型肺结核的临床疗效。
      方法将80例复治空洞型肺结核病人按随机数字表法均分为2组,各40例,对照组给予HRZES方案治疗,观察组在对照组基础上给予声动力靶位药物治疗。比较治疗2、4、8个月病灶吸收、空洞闭合、痰菌转阴以及并发症情况。
      结果观察组治疗2、4、8个月病灶吸收率、空洞闭合有效率以及痰菌转阴率均高于对照组(P < 0.05);2组治疗期间药物不良反应率差异无统计学意义(P>0.05)。
      结论声动力靶位药物传输联合HRZES方案治疗复治空洞型肺结核能促进空洞缩小、痰菌转阴以及病灶吸收,且不增加不良反应,治疗安全有效。

       

      Abstract:
      ObjectiveTo study the clinical effect of acoustic power target drug delivery combined with HRZES regimen on the retreatment of cavitary pulmonary tuberculosis.
      MethodsEighty patients with recurrent cavitary pulmonary tuberculosis were divided into two groups by the random number table method, with 40 cases in each group.The control group was treated with HRZES.The observation group was treated with acoustic power target drug delivery based on HRZES.Lesion absorption, cavity closure, sputum negative conversion and complications at 2, 4 and 8 months after treatment were compared.
      ResultsThe lesion absorption rate, cavity closure efficiency and sputum conversion rate in the observation group were significantly higher than those in the control group at 2, 4, and 8 months(P < 0.05).There was no significant difference in adverse reaction rate between the two groups(P>0.05).
      ConclusionsAcoustic power target drug delivery combined with HRZES regimen for retreatment of cavitary pulmonary tuberculosis is safe and effective, which can promote the cavity shrinkage, sputum negative conversion and lesion absorption without increasing adverse reactions.

       

    /

    返回文章
    返回